August 20, 2020 -- Johnson & Johnson has entered an agreement to acquire Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion with a tender offer to purchase all outstanding shares of Momenta for $52.50 per share.
The acquisition will expand Johnson & Johnson's ability to enter the autoantibody-driven disease market. The deal includes full global rights to nipocalimab (M281), a clinically validated anti- neonatal Fc receptor (FCRN) antibody. The drug has received a rare pediatric disease designation from the U.S. Food and Drug Administration. The company expects nipocalimab to help it achieve above-market growth in the mid and long term.
In addition to Momenta's employees and lead asset, Johnson & Johnson will acquire Momenta's full pipeline of clinical and preclinical assets. Johnson & Johnson plans to retain Momenta's presence in Cambridge, MA. The site will increase Johnson & Johnson's existing innovation footprint and capabilities in the greater Boston area.
The deal is expected to close in the second half of 2020.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
